Immunogenicity and safety of a new Vero cell rabies vaccine produced using serum-free medium

Vaccine

Volumn 25, Issue 48, 2007, Pages 8140-8145

  Costa, Wagner A ^a   Cunha, Ricardo S ^a   Bolzan, Vera Lucia ^a   Silva, Andrea de Cássia R ^a   Caporale, Graciane Maria M ^a   Chaves, Luciana B ^a   Oselka, Gabriel W ^b   Junqueira, Dulce A ^a   Panachão, Maria Rosana I ^a   Dias, Ricardo A ^b   Takaoka, Neide Y ^a  

^a Secretaria de Estado da Saude de Sao Paulo   (Brazil)

^b UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Rabies vaccine; Serum free medium; Vero cell

Indexed keywords

RABIES IMMUNOGLOBULIN; RABIES VACCINE;

ADULT; ARTICLE; BLOOD SAMPLING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CULTURE MEDIUM; DISEASE SEVERITY; DRUG COST; DRUG SAFETY; FEMALE; FEVER; HEADACHE; HUMAN; HUMAN EXPERIMENT; IMMUNOGENICITY; INJECTION SITE EDEMA; INJECTION SITE ERYTHEMA; INJECTION SITE INDURATION; INJECTION SITE PAIN; INJECTION SITE PRURITUS; MALAISE; MALE; MYALGIA; PRIORITY JOURNAL; PRURITUS; RABIES; RABIES VIRUS; RANDOMIZED CONTROLLED TRIAL; SEROCONVERSION; SOMNOLENCE; VACCINATION; VERO CELL; WORLD HEALTH ORGANIZATION;

ADULT; ANIMALS; ANTIBODIES, VIRAL; CERCOPITHECUS AETHIOPS; HUMANS; MIDDLE AGED; RABIES; RABIES VACCINES; RABIES VIRUS; SAFETY; TREATMENT OUTCOME; VERO CELLS;

EID: 35748984110     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2007.09.043     Document Type: Article

References (27)

1. WHO expert consultation on rabies: first report. WHO Technical Report Series, No. 931. Geneva: World Health Organization; 2004.
2. Plotkin S.A., Rupprecht C.E., and Koprowski H. Rabies vaccine. In: Plotkin S.A., and Orenstein W.A. (Eds). Vaccines. 3rd ed. (1999), WB Saunders Company, Philadelphia 743-766
3. WHO Expert Committee on Rabies. Eight report. WHO Technical Report Series, No. 824. Geneva: World Health Organization; 1992.
4. Montagnon B., and Fanget B. Purified Vero cell vaccine for humans. In: Meslin F.-X., Kaplan M.M., and Koprowski H. (Eds). Laboratory techniques in rabies (1996), WHO, Geneva 285-289
5. Froud S.J. The development, benefits and disadvantages of serum-free media. Dev Biol Stand 99 (1999) 157-166
6. Merten O.W. Development of serum-free media for cell growth and production of viruses/viral vaccines-safety issues of animal products used in serum-free media. Dev Biol 111 (2002) 233-257
7. Dobardzic A., Izurieta H., Woo E.J., Iskander J., Shadomy S., Rupprecht C., et al. Safety review of the purified chick embryo cell rabies vaccine: data from the Vaccine Adverse Event Reporting System (VAERS), 1997-2005. Vaccine 25 (2007) 4244-4251
8. Frazatti-Galinna N.M., Morao-Fuches R.M., Paoli R.L., Silva M.L.N., Miyaki C., Valentini E.J.G., et al. Vero-cell rabies vaccine produced using serum-free médium. Vaccine 23 (2004) 511-517
9. Brasil. Ministério da Saúde. Fundação Nacional de Saúde. Centro Nacional de Epidemiologia. Coordenação de Controle de Zoonoses e Animais Peçonhentos. Programa Nacional de Profilaxia da raiva. Normas Técnicas de Tratamento Profilático Anti-Rábico Humano. Brasília; 2002. http://saude.pr.gov.br/ftp/Saudeambiental/NORMA_TECNICA_DA_RAIVA_%202002.doc.
10. Smith J.A., Yanger P.A., and Baer G.M. Rapid fluorescent focus inhibition test for determining rabies virus-neutralizing antibody. In: Meslin F.-X., Kaplan M.M., and Koprowski H. (Eds). Laboratory techniques in rabies (1996), WHO, Geneva 181-192
11. Suntharasamai P., Warrell M.J., Warrell D.A., Viravan C., Looareesuwan S., Supanaranond W., et al. New purified Vero-cell rabies vaccine prevents rabies in patients bitten by rabid animals. Lancet 2 8499 (1986) 129-131
12. Suntharasamai P., Chanthavanich P., Warrell M.J., Looareesuwan S., Karbwang J., Supanaranond W., et al. Purified Vero cell rabies vaccine and human diploid cell strain vaccine: comparison of neutralizing antibody responses to post-exposure regimens. J Hyg (Lond) 96 3 (1986) 483-489
13. Klietmann W., Klietmann B., Cox J., and Charbonnier C. Effectiveness and tolerance of pre- and postexposure treatment with purified inactivated rabies vaccine prepared on Vero cell line. Vaccine 6 1 (1988) 39-43
14. Seghal S., Bhattacharya D., and Bhardwaj M. Five-year longitudinal study of efficacy and safety of purified Vero cell rabies vaccine for post-exposure prophylaxis of rabies in Indian population. J Commun Dis 29 1 (1997) 23-28
15. Benjavongkulchai M., Kositprapa C., Limsuwun K., Khawplod P., Thipkong P., Chomchey P., et al. An immunogenicity and efficacy study of purified chick embryo cell culture rabies vaccine manufactured in Japan. Vaccine 15 (1997) 1816-1819
16. Jaiiaroensup W., Lang J., Thipkong P., Wimalaratne O., Samranwataya P., Saikasem A., et al. Safety and efficacy of purified Vero cell rabies vaccine given intramuscularly and intradermally. (Results of a prospective randomized trial). Vaccine 16 16 (1998) 1559-1562
17. Quiambao B.P., Lang J., Vital S., Montalban C.G., Le Mener V., Wood S.C., et al. Immunogenicity and effectiveness of post-exposure rabies prophylaxis with a new chromatographically purified Vero-cell rabies vaccine (CPVR): a two-stage randomized clinical trial in the Philippines. Acta Trop 75 (2000) 39-52
18. Jones R.L., Froeschle J.E., Atmar R.L., Matthews J.S., Sanders R., Pardalos J., et al. Immunogenicity, safety and lot consistency in adults of a chromatographically purified Vero-cell rabies vaccine: a randomized, double-blind trial with human diploid cell rabies vaccine. Vaccine 19 (2001) 4635-4643
19. Sampath G., Reddy S.V., Rao M.L., Rao Y.U., and Palaniappan C. An immunogenicity study of a newly introduced purified Vero cell rabies vaccine (Abhayrab) manufactured in India. Vaccine 23 (2005) 897-900
20. Matha I.S., and Salunke S.R. Immunogenicity of purified vero cell rabies vaccine used in the treatment of fox-bite victims in India. Clin Infect Dis 40 4 (2005) 611-613
21. Briggs D.J., Banzhoff A., Nicolay U., Sirikwin S., Dumavibhat B., Tongswas S., et al. Antibody response of patients after postexposure rabies vaccination with small intradermal doses of purified chick embryo cell vaccine or purified Vero cell rabies vaccine. Bull World Health Organ 78 5 (2000) 693-698
22. Strady A., Lang J., Lienard M., Blondeau C., Jaussaud R., and Plotkin S.A. Antibody persistence following preexposure regimens of cell-culture rabies vaccines: 10 years follow-up and proposal for a new booster policy. J Infect Dis 177 (1998) 1290-1295
23. Strady C., Jaussaud R., Béguinot I., Lienard M., and Strady A. Predictive factors for the neutralizing antibody response following pre-exposure rabies immunization: validation of a new booster dose strategy. Vaccine 18 (2000) 2661-2667
24. Brinkman D.M., Jol-van der Zijde C.M., ten Dam M.M., Vossen J.M., Osterhaus A.D., Kroon F.P., et al. Vaccination with rabies to study the humoral and cellular immune response to a T-cell dependent neoantigen in man. J Clin Immunol 23 (2003) 528-538
25. van Zelm M.C., Reisli I., van der Burg M., Castaño D., van Noelsel C.J., van Tol M.J., et al. An antibody-deficiency syndrome due to mutations in the CD19 gene. N Engl J Med 354 (2006) 1874-1877
26. Zuckerman J.N. Nonresponse to hepatitis B vaccines and kinetics of anti-HBs production. J Med Virol 50 (1996) 283-288
27. Zuckerman J.N. Protective efficacy, immunotherapeutic potential, and safety of hepatitis B vaccines. J Med Virol 78 (2006) 169-177